longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

300705

300705
10.882.42%( -0.27 )

LongbridgeAI

JIUDIAN PHARMACEUTICAL: The Phase III clinical trial report for Jiaoqi Pain Relief Gel Patch has been released

Zhitong
Sep 1, 2025 at 10:09 AM

JIUDIAN PHARMACEUTICAL announced that the company recently obtained the summary report of the Phase III clinical trial for the Jiao Qi Pain Relief Gel Patch. The results show that the drug is significantly effective in improving pain caused by knee osteoarthritis. The trial group showed significant differences compared to the placebo group in terms of changes in VAS pain scores for the target side knee joint after 2 weeks and 1 week of medication, pain relief effectiveness rate, changes in total WOMAC scores, and total effective rate of Traditional Chinese Medicine syndromes. Additionally, the onset time for pain relief was faster. Furthermore, the trial group occasionally experienced mild adverse reactions such as itching and skin burning sensation, with no serious adverse reactions reported, indicating good safety. The drug is convenient to use and is worthy of clinical promotion. The company will continue to advance the registration application, and it can only be marketed after approval

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

JIUDIAN PHARMACEUTICAL

JIUDIAN PHARMACEUTICAL

300705.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--